Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In … – Seeking Alpha

Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In
Seeking Alpha
After the close of the markets on Wednesday, October 9, 2013, Dynavax (DVAX) announced it will begin dosing patients in the first human trial in its asthma program. The trial, which is being conducted under a collaborative agreement with AstraZeneca

View full post on asthma – Google News

Dynavax starts Phase I trial of asthma treatment – San Francisco Business Times (blog)

Dynavax starts Phase I trial of asthma treatment
San Francisco Business Times (blog)
The Berkeley company (NASDAQ: DVAX) will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo. If all goes well, 
DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human 4-traders (press release)
Dynavax Initiates First Human Trial in Asthma ProgramMENAFN.COM

all 3 news articles »

View full post on asthma – Google News

Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program – PR Newswire (press release)

Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
PR Newswire (press release)
SAN FRANCISCO, June 4, 2013 /PRNewswire/ — Tunitas Therapeutics, Inc., a private company discovering and developing novel human fusion proteins for the treatment of asthma and other allergic diseases, has been awarded a Small Business Innovation

and more »

View full post on asthma – Google News

Phase III Success for Boehringer Ingelheim Asthma Drug – Genetic Engineering News

Phase III Success for Boehringer Ingelheim Asthma Drug
Genetic Engineering News
Boehringer-Ingelheim said today its once-daily asthma drug tiotropium, delivered via Respimat® Soft Mist™ Inhaler, produced favorable Phase III results by increasing the time to first severe exacerbation, and time to first episode of asthma worsening
Boehringer Ingelheim's tiotropium shows promising results in patients with News-Medical.net
Phase III results: tiotropium* Respimat® effective in symptomatic asthma EON: Enhanced Online News (press release)
Boehringer Ingelheim reports positive data from symptomatic asthma trialsZenopa

all 5 news articles »

View full post on asthma – Google News

Phase III Study: Tiotropium Effective In Symptomatic Asthma Patients – Science 2.0 – Science 2.0

Phase III Study: Tiotropium Effective In Symptomatic Asthma Patients – Science 2.0
Science 2.0
Tiotropium delivered by the Respimat(R) Soft Mist(TM) Inhaler (SMI) increases time to first severe exacerbation and first episode of asthma worsening across a broad spectrum of patients who remain symptomatic despite at least inhaled corticosteroids
Phase III results: tiotropium(*) Respimat(R) effective in symptomatic asthma Wall Street Journal (press release)
Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a PR Newswire (press release)

all 4 news articles »

View full post on asthma – Google News

Nitric oxide and its metabolites in the critical phase of illness: rapid biomarkers in the making.

Related Articles

Nitric oxide and its metabolites in the critical phase of illness: rapid biomarkers in the making.

Open Biochem J. 2013;7:24-32

Authors: Mian AI, Aranke M, Bryan NS

Abstract
The potential of nitric oxide (NO) as a rapid assay biomarker, one that could provide a quantum leap in acute care, remains largely untapped. NO plays a crucial role as bronchodilator, vasodilator and inflammatory mediator. The main objective of this review is to demonstrate how NO is a molecule of heavy interest in various acute disease states along the emergency department and critical care spectrum: respiratory infections, central nervous system infections, asthma, acute kidney injury, sepsis, septic shock, and myocardial ischemia, to name just a few. We discuss how NO and its oxidative metabolites, nitrite and nitrate, are readily detectable in several body compartments and fluids, and as such they are associated with many of the pathophysiological processes mentioned above. With methods such as high performance liquid chromatography and chemiluminescence these entities are relatively easy and inexpensive to analyze. Emphasis is placed on diagnostic rapidity, as this relates directly to quality of care in acute care situations. Further, a rationale is provided for more bench, translational and clinical research in the field of NO biomarkers for such settings. Developing standard protocols for the aforementioned disease states, centered on concentrations of NO and its metabolites, can prove to revolutionize diagnostics and prognostication along a spectrum of clinical care. We present a strong case for developing these biomarkers more as point-of-care assays with potential of color gradient test strips for rapid screening of disease entities in acute care and beyond. This will be relevant to global health.

PMID: 23539501 [PubMed – in process]

View full post on pubmed: asthma

The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study … – PR Newswire (press release)

The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study
PR Newswire (press release)
Cytos Biotechnology Ltd (SIX:CYTN) today announced the publication of the results from its phase 2a clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma.

and more »

View full post on asthma – Google News